发明名称 |
Purified antibody composition |
摘要 |
The invention provides a method for producing a host cell protein-(HCP) reduced antibody preparation from a mixture comprising an antibody and at least one HCP, comprising an ion exchange separation step wherein the mixture is subjected to a first ion exchange material, such that the HCP-reduced antibody preparation is obtained. |
申请公布号 |
US9096666(B2) |
申请公布日期 |
2015.08.04 |
申请号 |
US201414550809 |
申请日期 |
2014.11.21 |
申请人 |
AbbVie Biotechnology Ltd |
发明人 |
Wan Min M;Avgerinos George;Zarbis-Papastoitsis Gregory |
分类号 |
A61K39/395;C07K16/24;C07K1/18;C07K1/36;C07K16/06;A61K39/00 |
主分类号 |
A61K39/395 |
代理机构 |
Ropes & Gray LLP |
代理人 |
Ropes & Gray LLP ;Li Z. Ying;Gavin Brendan A. |
主权项 |
1. A liquid composition comprising adalimumab, wherein the adalimumab is expressed in a Chinese Hamster Ovary (CHO) cell expression system; and the composition is characterized in that when the composition is assayed in a cathepsin L kinetic assay, a level of cathepsin L activity less than 1.84 RFU/s/mg of adalimumab is observed, wherein the cathepsin L kinetic assay comprises:
i) diluting the composition in a polystyrene container in a solution containing 25 mM NaOAc, 5 mM DTT and 1 mM EDTA at pH 5.5, ii) adding dextran sulfate to a concentration of 0.035 μg/mL and incubating at 37° C. for six hours, iii) adding Z-leucine-arginine covalently bound at its C-terminus to a fluorescent 7-amino-4-methyl coumarin (Z-leucine-arginine-AMC), wherein the diluting, adding, and incubating steps are sufficient to permit the measurement of cathepsin L hydrolysis of the Z-leucine-arginine-AMC within a linear range, and iv) measuring Z-leucine-arginine-AMC hydrolysis in the linear range in RFU/s/mg of adalimumab. |
地址 |
Hamilton BM |